About Us
CRISPRomics®
+
CRISPRomics®
Publications
Pipeline
+
Pipeline®
Expanded Access Policy
News
People
+
Leadership Team
Board of Directors
Careers
Contact
Follow us on Twitter
Find us on LinkedIn
EORTC-NIC-AACR 2022
October 26, 2022
“KSQ-4279, a first-in-class USP1 inhibitor shows strong combination activity in BRCA mutant cancers with intrinsic or acquired resistance to PARP inhibitors”
© 2023 KSQ Therapeutics, Inc. All rights reserved.